Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798
Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food ... Read More
Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) ... Read More
HemaCare to be acquired by Charles River Laboratories for $380m
Charles River acquisition of HemaCare : Charles River Laboratories International, an early-stage contract research organization, has agreed to acquire HemaCare for about $380 million in ... Read More
Amarin bags Vascepa FDA approval for reducing cardiovascular risk
Vascepa FDA approval : New Jersey-based Amarin has secured approval from the US Food and Drug Administration (FDA) for a new indication and label expansion ... Read More
Glaukos closes Avedro acquisition to expand corneal health franchise
Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its previously announced acquisition of Avedro. Based in ... Read More
CD&R to acquire Cynosure medical aesthetics business from Hologic for $205m
Clayton, Dubilier & Rice (CD&R), a New York-based private equity firm, has signed an all-cash deal worth $205 million to acquire Cynosure, a medical aesthetics ... Read More
CD&R to acquire Cynosure medical aesthetics business from Hologic for $205m
Clayton, Dubilier & Rice (CD&R), a New York-based private equity firm, has signed an all-cash deal worth $205 million to acquire Cynosure, a medical aesthetics ... Read More
3M to sell drug delivery business to Altaris Capital for $650m
US industrial conglomerate 3M has signed a cash-cum-stock deal worth around $650 million to sell substantially all of its drug delivery business to an affiliate ... Read More
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More
Leucadia launches Sodium Tetradecyl Sulfate injection for varicose veins
Leucadia Pharmaceuticals, the commercial sales unit of Custopharm, has launched the FDA-approved Sodium Tetradecyl Sulfate (STS) generic injection in the US. According to Leucadia Pharmaceuticals, ... Read More